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Abstract
Background: In the context of national and regional goals to eliminate malaria by 2030, the Center for Malaria Parasitology and Entomology in the Lao PDR is implementing strategies to ensure all malaria cases are detected and appropriately treated with first-line artemisinin combination therapy, artemether–lumefantrine (AL). Timely and relevant
evidence to inform policies and strategies is needed to ensure the most effective and efficient use of resources, and to
accelerate progress towards elimination goals. A 2015 outlet survey conducted in five provinces of the southern Lao
PDR was the first of its kind to study the total market for malaria treatments and diagnostics. The sub-national outlet
survey was designed to describe the market and to assess public and private sector readiness and performance for
malaria case management. Additionally, key indicators were estimated among private outlets within districts with and
without a Public Private Mix (PPM) programme.
Results: Over half of anti-malarial stockists were public sector (65.1%). In the private sector, pharmacies most commonly stocked anti-malarials, although anti-malarials were also found in private health facilities, drug stores, general
retailers, and itinerant drug vendors. Nearly all anti-malarial stocking public health facilities had AL (99.5%) and 90.8%
had confirmatory testing. Fewer than half of anti-malarial stocking private outlets stocked AL (40.8%) and malaria
testing (43.5%). Chloroquine has not been a first-line treatment for Plasmodium falciparum malaria since 2005 and
Plasmodium vivax since 2011 yet private sector availability was 77.6% and chloroquine accounted for 62.2% of the
total anti-malarial market share. AL and confirmatory testing availability were higher in private outlets in PPM (68.1,
72.6%) versus non-PPM districts (2.5, 12.1%). Chloroquine was available in 63.6% of PPM and 96.7% of non-PPM-district
outlets, and was the most commonly distributed anti-malarial among private outlets in both PPM (61.7%) and nonPPM districts (99.1%).
Conclusions: Public sector outlets in the southern Lao PDR are typically equipped to test and appropriately treat
malaria. There is need to address widespread private sector availability and distribution of chloroquine. The PPM
programme has improved private provider readiness to manage malaria according to national guidelines. However,
supporting interventions to address provider and consumer behaviours are needed to further drive uptake.
Keywords: Lao PDR, Case management, Private sector, Public private mix, Chloroquine, ACT, Anti-malarial
Background
Important gains in malaria control have been achieved
in recent years in the Lao, People’s Democratic Republic
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(PDR). Malaria admissions and deaths have declined
substantially since 2000. However, a 2011 outbreak in
the southern provinces has been associated with a spike
in cases and deaths. Case numbers have not returned to
the seasonal low levels observed prior to 2011, suggesting an ongoing outbreak [1]. In 2015, there were over
48,000 reported confirmed positive malaria cases, up
from 38,131 cases in the previous year [1, 2]. Approximately 31% of the Lao PDR’s population of 6.6 million
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live in areas of high transmission and another 61% live in
areas of low transmission. The vast majority (95%) of the
malaria burden is concentrated in the southern five provinces. Plasmodium falciparum makes up 62% of the parasite species while Plasmodium vivax comprises the other
38% [2]. Artemether–lumefantrine (AL) was introduced
as the first-line treatment for uncomplicated P. falciparum malaria in 2005 and P. vivax malaria in 2011.
The Lao PDR has set the goal of eliminating P. falciparum malaria by 2025 and all forms of malaria by 2030.
In line with the World Health Organization’s (WHO)
Strategy for Malaria Elimination in the Greater Mekong
Subregion, the dual goal has been set to both interrupt
transmission of P. falciparum in areas of multidrug resistance as well as reduce malaria transmission in high transmission areas to less than one case per 1000 population
at risk by 2020 [1, 3].
Detecting and appropriately treating all malaria cases is
critical to achieving elimination goals in the Lao PDR. In
order to bolster proper testing and treatment practices, the
Center for Malaria Parasitology and Entomology (CMPE)
has devoted significant resources in recent years to ensuring that public health facilities are stocked with appropriate first-line artemisinin combination therapy (ACT) and
malaria rapid diagnostic tests (RDTs). Malaria diagnosis has been free of charge in the public sector since the
beginning of 2005 [1]. In 2010, CMPE began procuring
RDTs capable of detecting both P. falciparum and P. vivax
parasites, which increased the number of reported cases.
CMPE expanded access to appropriate test and treat
services to the community-level through the training and equipping of Village Malaria Workers as well as
some existing Village Health Volunteers for proper testing and treating of malaria in endemic areas. The Community Health Worker (CHW) programme for malaria
case management using RDT and ACT was introduced
in 2005. In 2016, a total of 5825 CHWs with malaria case
management training and equipment were counted [1].
Activities aimed at strengthening the CHW network are
highly prioritized and are scheduled to receive USD $4.2
million over the next 5 years [1].
CMPE has also extended access to appropriate malaria
case management through leveraging the private sector. The Public Private Mix (PPM) programme commenced in 2008 as a way of introducing first-line ACT
and RDT into the highly utilized private sector. Participating pharmacies and private for-profit facilities were
supplied with AL and RDTs through the existing government supply chain. Participating outlets were permitted
to sell the products at a small profit, though many providers reportedly chose to dispense AL free of charge [4].
The PPM pilot initially included 10 private clinics and 85
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pharmacies from 8 districts across 4 provinces. By 2012,
the programme expanded to 16 clinics and 245 pharmacies from 22 districts across 8 provinces [4]. According to
government policy, only PPM pharmacies are authorized
to dispense anti-malarials.
In line with the National Strategic Plan, CMPE and
other implementing partners, will continue to address
malaria case management gaps that are critical to achieving progress towards malaria elimination over the next
5 years. Timely and relevant evidence to inform case
management policies and strategies is needed to ensure
the most effective and efficient use of resources, and to
accelerate progress towards elimination goals. However,
substantial evidence gaps exist with respect to the total
market for malaria testing and treatment in the southern
Lao PDR, including case management readiness and performance of providers across the public and private sectors. Understanding the private sector in the Lao PDR
will be particularly important given this is an important
treatment channel [5].
The ACTwatch project is a multi-country research
project launched in 2008 by Population Services International (PSI) and London School of Hygiene and Tropical Medicine (LSHTM) with support from the Bill and
Melinda Gates Foundation. The goal of ACTwatch is to
fill contemporary evidence gaps by collecting malaria
case management market data on anti-malarial treatments and malaria diagnostics in both the private and
public sector. ACTwatch provides timely, high quality
and relevant anti-malarial market data so as to inform
and monitor national, regional and global malaria case
management policy, strategy and funding decisions [6, 7].
The 2015 ACTwatch outlet survey was the first of its
kind to be conducted in the Lao PDR. The objective of
this paper is to provide practical evidence to inform the
malaria elimination strategy and policy in the Lao PDR.
The paper describes the total market for malaria treatments and diagnostics in the five southern provinces of
the Lao PDR with highest malaria burden. Key indicators
are presented including a description of the market, readiness to test and treat in public and private sectors, antimalarial market share, and provider knowledge. Evidence
on the total market, as well as on outcomes associated
with the PPM programme, will point to recommendations for rapidly improving coverage of appropriate
malaria case management in the southern Lao PDR.

Methods
Design and sampling

A representative cross-sectional outlet survey was conducted amongst a sample of outlets stocking malaria testing and/or treatment in five southern provinces in the
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Lao PDR (Savannakhet, Champasack, Salavanh, Sekong
and Attapeu). According to the ACTwatch methodology, outlets are included in the survey if they have the
‘potential’ to sell or distribute anti-malarials or diagnostic testing. This includes outlets that may not typically
be expected to stock anti-malarial treatments, such as
general retailers, village shops, or itinerant drug vendors.
However, it is recognized that in many countries these
outlets can operate as vendors for anti-malarial commodities, either illegally or/and outside of the formal health
system. As such, in many instances outlets are included
in the sample as a means to confirm their role or presence in a given country’s anti-malarial and diagnostic
market. These outlets may differ on a country by country
basis, but overall broad categories are used to define public and private sector outlets.
In the Lao PDR, outlets with the potential to sell or distribute included public health facilities (provincial hospitals, district hospitals and health centers) and CHWs
(village malaria workers and village health volunteers).
Private sector outlets included private for-profit health
facilities and pharmacies. The private for-profit facility category consisted of private hospitals, clinics and
diagnostic laboratories. The pharmacy category consisted of clinical pharmacies and level 1, 2 and 3 pharmacies. Clinical pharmacies are those that offer clinical
and pharmaceutical services despite only being licensed
to offer pharmaceutical services. Level 1 pharmacies are
large, can act as wholesalers and have pharmacists on
staff to advise patients on treatment. Level 2 pharmacies, while smaller, can still act as wholesalers but only
sometimes have pharmacists on staff to advise patients.
Level 3 pharmacies are small and the owner, who is not
a pharmacist, is renting a pharmacy license from a pharmacist. Informal private sector outlets were also included
in the outlet survey, including drug stores, general retailers and itinerant drug vendors. Drug stores were defined
as unregistered rural market or home stalls that primarily sold treatments and were not necessarily staffed by a
trained pharmacist. General retailers consisted of grocery
stores and village shops selling fast-moving consumer
goods. Itinerant drug vendors were unregistered mobile
drug vendors generally catering to mobile migrant communities. Outlets that did not serve the general public
were excluded from the outlet survey, however military
and police facilities that served the general public were
included.
The primary sampling approach taken for ACTwatch
outlet surveys entails sampling a set of administrative
units (geographic clusters) with a population of approximately 10,000–15,000 inhabitants. Clusters are selected
with cluster probability of selection proportionate to
size (PPS). A census of all outlets with the potential to
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sell or distribute anti-malarials is then conducted in
sampled clusters, given a sampling frame for all potentially eligible outlet types is not available. The most
appropriate administrative unit in the Lao PDR matching
the desired population size was a village group. The village group was an administrative unit with populations
smaller than districts but larger than individual villages.
Most village groups include between five and ten villages.
Village groups were selected with PPS using population estimates obtained from the Lao National Statistics
Centre.
Given this was the first ACTwatch outlet survey implemented in the Lao PDR, and previous information on the
number of outlets or first-line treatment was not available, a series of calculations and assumptions were made
to identify minimum sample size requirements. The sample size was developed to estimate with precision (±7.5
percentage points) the proportion of outlets with firstline anti-malarial treatments available, among outlets
with anti-malarial(s) in stock on the day of the survey for
all public health facilities and private for-profit facilities
and pharmacies. The required sample size was calculated in three steps: (1) determine the required number
of anti-malarial-stockists; (2) determine the number of
clusters (village groups) for the census to arrive at this
number of outlets; (3) determine the required number
of village groups. Available information on numbers of
public and private sector outlets per village group were
used to determine the optimal number of clusters for the
outlet survey. National outlet lists provided by the Food
and Drug Department and Health Care Department were
used to determine the number of public health facilities
and private registered outlet types per village group. On
average, in the Southern Lao PDR there were around 3.3
public health facilities and regulated private outlets per
village group. Based on these assumption, a sample size
of 77 village groups was selected in order to estimate
key indicators on availability of first-line treatment and
malaria testing with 95% confidence and a maximum
tolerable error of 5%. A design effect of 2 was used to
account for cluster sampling in the context of what was
anticipated to be a high degree of homogeneity in the
anti-malarial market within and across clusters.
To estimate indicators within the private sector with
precision, the boundary for the census of pharmacies
and private for-profit health facilities was extended to the
district level. This ‘booster sample’ of formal private sector outlets covered all pharmacies and private for-profit
health facilities within 41 of the 42 distributed in the
five study provinces allowing for a sufficient sample size
to allow for precise comparisons between these important but less common facility types Within each selected
cluster, a census of all the aforementioned outlets was
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conducted. To identify outlets, interviewers would walk
systematically through each of the selected clusters looking for relevant outlets. Lists of registered outlets, such
as public health facilities or pharmacies, were obtained
prior to the data collection and used to help identify
outlets. To identify itinerant drug vendors, congregation
points or locations were identified using key informant
interviews. These providers were approached by interviewers and asked if they had already participated in the
survey to avoid duplication. Outlets were screened to
assess eligibility for the outlet survey. Outlets were eligible for a provider interview and malaria product audit if
they met at least one of three study criteria: (1) one or
more anti-malarials reportedly in stock on the day of the
survey; (2) one or more anti-malarials reportedly in stock
within the 3 months preceding the survey; and/or (3) had
malaria blood testing (microscopy or RDT).
Measures

The outlet survey was conducted using a paper questionnaire. The questionnaire was translated from English to
Lao and then back to English to confirm valid translations in Lao. Outlets meeting eligibility criteria noted
above were invited to participate in the survey. Following informed consent procedures, an audit of all available
anti-malarial treatments and RDTs was conducted. Antimalarial audit information included formulation, package
size, brand name, active ingredients and strengths, manufacturer, country of manufacture, reported sale/distribution in the week preceding the survey, retail price, and
wholesale price. The RDT product audit collected similar
information, but excluded questions on pack size, formulation, strength and active ingredients. In addition to the
product audit, a series of questions was administered to
the senior-most provider regarding malaria case management knowledge and practices, as well as provider
training and qualifications and reporting on malaria case
load data (Additional file 1: Survey questionnaire in English, Additional file 2: Survey questionnaire in Lao language). Geo-coordinates were recorded for each outlet
using a handheld Global Positioning System (GPS) unit.
Up to three visits were made to all outlets to complete
the screening process, audit, and provider interview, as
needed (e.g. where outlets were closed or providers were
not available).
Training and data collection

All standardized training materials were adapted to fit
within the context of the southern Lao PDR. A 1-week
training of trainers was held in October 2015, followed by
a 2-day pilot to test the ACTwatch outlet survey instruments in the Lao PDR context. A 6-day data collector
training was then held, followed by a 2-day data collector
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field exercise in order to give newly trained data collectors practice with the study methodology and tools. High
performers identified during data collector training were
selected for a further 3 days of supervisor and quality
controller training.
Five data collection teams were created after the conclusion of training. Each team was comprised of one
supervisor, one quality controller and three to four data
collectors. Two PSI/Lao platform and two research
agency staff offered higher-level logistical and data quality supervision. Field operations were supervised and
managed by an ACTwatch team-member.
A 4-day double data entry and data coding training was
also conducted. A supervisor, two coders and ten data
entry clerks were trained in appropriate coding, translation and data entry techniques. The supervisor oversaw
all data coding and entry processes and notified ACTwatch staff if any issues arose.
Peak malaria transmission season in the Lao PDR is
July–October. Due to delays in study approval, data collection took place between November 18th and December 29th, 2015. Upon a data collection team’s arrival to
a district within a selected cluster, data collector team
supervisors met with district officials to crosscheck their
list of public and formal private sector outlets with that of
the government list. Data collection teams then travelled
to the selected cluster and met with the village group
head. These meetings generally yielded sketch maps of
the villages, which were useful for data collection teams
during the census process.
A Microsoft Access (Microsoft Corporation, Redmond,
Washington, USA) database with built-in range checks
was used to conduct double data entry from physical
questionnaires shipped from the study area to Vientiane.
Daily supervisor and data collector monitoring sheets
were collated in a Microsoft Excel (Microsoft Corporation, Redmond, Washington, USA) spreadsheet, which
along with the physical questionnaires, were used to triangulate entered data.
Protection of human subjects

The 2015 outlet survey protocol received ethical
approval from the National Ethics Committee for Health
Research in the Lao PDR (approval number 059 NIOPH/
NECHR). Provider interviews and product audits were
completed only after administering a standard informed
consent form and provider consent to participate in
the outlet survey. Providers had the option to end the
interview, which was conducted in a private place, at
any point during the outlet survey. Standard measures were employed to maintain provider confidentiality and anonymity. Fieldworker training instructed and
assessed understanding of these standard precautions
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for protecting human subjects among all people working
on the study. All information provided by respondents
was strictly confidential and used only for study purposes. All data collectors were instructed and monitored
to ensure that they did not share information about individual outlets or providers with community members or
local leaders. Information about individual outlets was
not shared with any national authorities. Results were
not linked to individual providers or outlets. Respondent
names and outlet names were not stored with the final
clean data.
Data analysis

Stata 13 (StataCorp, College Station, Texas, USA) was
used to analyse data imported from the Access database.
Survey settings were used to account for the study design
and included sampling weights, calculated as the inverse
of probability of village group selection.
Standard ACTwatch indicators were calculated [6,
7]. Briefly, anti-malarials were classified as ACT, nonartemisinin therapy, and oral or non-oral artemisinin
monotherapy.
Availability was defined in this study as the proportion
of outlets stocking at least one anti-malarial, among censused outlets. Other anti-malarial and RDT availability
categories were calculated but restricted to those outlets
where at least one anti-malarial was audited. For example, ACT availability (the proportion of ACT-stockists)
was measured as the number of ACT-stockists in the
numerator and the number of anti-malarial stockists in
the denominator.
Market share was defined as the relative distribution
of the anti-malarials to individual consumers in the week
preceding the survey. In order to allow for meaningful
market share comparisons between products, information about anti-malarial distribution was standardized
to the adult equivalent treatment dose (AETD). AETD is
the amount of active ingredient necessary to treat a 60 kg
adult according to WHO treatment guidelines [8]. Volumes distributed were calculated by converting provider
reports on the number of anti-malarials sold in the week
prior to the survey into AETDs. Volumes were, therefore,
the number of AETDs sold or distributed by a provider in
the 7 days prior to the survey. All dosage forms were considered in measuring volumes so as to provide a complete
assessment of anti-malarial market share. Private sector
booster sample outlets were excluded from market share
calculations to avoid over-estimating the role of the private sector.
Median private sector price per AETD was calculated
for the first-line ACT and for chloroquine, and for RDT
testing including consultation and service fees. Interquartile range (IQR) was calculated to demonstrate price
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dispersion. Anti-malarial and RDT price was collected in
Lao Kip and converted to the US dollars based on official
exchange rates for the 6-week data collection period.
Provider knowledge was assessed by administering
knowledge questions to the senior most provider at all
anti-malarial-stockists. The senior-most provider was
questioned because he or she generally holds the most
knowledge regarding diagnosis and prescription practices at the outlet. In all but one case, data collectors
were able to interview the senior-most provider at eligible outlets. The one outlet in which the senior-most provider was not available was dropped from the data set.
Provider knowledge was assessed in two ways—knowledge of national first-line treatment and dosing regimen for uncomplicated P. falciparum/P. vivax malaria
for a 60 kg adult as well as dosing regimen for uncomplicated P. falciparum/P. vivax malaria for a 60 kg adult.
Dosing regime knowledge assessment components
included questions on the number of tablets per dose,
number of times per day and number of days in the
regimen.
Among the 41 study districts, there were 25 districts
with and 16 districts without the PPM programme. PPM
programme designation for each district was obtained
from CMPE. Private for-profit facilities or pharmacies were defined as being part of the PPM programme
according to their designated location. Outlets that were
located in PPM districts were designated as ‘PPM outlets’,
and those outlets that were located in non-PPM districts
were defined as ‘non-PPM’ outlets. Only private for-profit
facilities and pharmacies were classified as PPM or nonPPM outlets, given these were the outlet types targeted
by the programme. Other outlet types, such as public
health facilities and general retailers were excluded from
the PPM definition. Key private sector indicators including availability, anti-malarial market share, and price
were calculated among the private sector PPM and nonPPM outlets.

Results
A total of 7586 outlets were screened for availability of
anti-malarials and/or malaria blood testing services. Of
screened outlets, 725 were stocking anti-malarials or
malaria blood testing on the day of the survey or within
the past 3 months, and 724 were subsequently interviewed, as one eligible respondent was not available for
interview. A total of 1666 anti-malarial and 483 RDT
products were audited (Additional file 3: detailed sample
description).
Availability

Across all screened outlets in the public sector (N = 558),
97.8% of public health facilities and 34.8% of CHWs stocked
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at least one anti-malarial on the day of survey. Across all
screened outlets in the private sector (N = 7028), availability of any anti-malarial was 6.5%. Private sector availability
was highest among pharmacies (70.6%; N = 479) followed
by private for-profit facilities (36.2%, N = 172), drug stores
(22.0%, N = 15) and itinerant drug vendors (5.3%, N = 67).
Of the 6295 general retailers screened, 0.5% stocked at least
one anti-malarial (Fig. 1).
Market composition

Figure 2 illustrates the relative distribution of outlets with
at least one anti-malarial in stock on the day of survey
(N = 402). Among anti-malarial stockists, 67.2% were
public sector outlets, made up of CHWs (42.5%) and
public health facilities (22.6%). 22.8% of anti-malarial
service delivery points were pharmacies. General retailers and private for-profit facilities each accounted for 6.0
and 4.3% of the market composition respectively. Itinerant drug vendors accounted for just 1% of the anti-malarial market composition.
Availability of anti‑malarials and blood testing

Table 1 illustrates availability of different types of antimalarials and malaria blood testing, among outlets that
were stocking at least one anti-malarial. Among antimalarial stockists in the public sector (N = 236), availability of the national first-line ACT (AL) was 88.8%, with
almost universal availability among public health facilities

N=402

Public Health Facility
Community Health Worker
Private for-Profit Health Facility
Pharmacy
Drug Store
General Retailer
Itinerant Drug Vendor

Fig. 2 Anti-malarial market composition

(99.5%). Availability among CHWs was 83.1%. In the antimalarial stocking private sector (N = 394), 63.3% of private for-profit facilities and 51.7% of pharmacies stocking
at least one anti-malarial had AL in stock. All AL available
in the public and private sectors was considered qualityassured given that all audited AL products were listed
on the World Health Organization’s pre-qualification list
and/or the Global Fund list of approved anti-malarials.
Availability of chloroquine among anti-malarial stocking public health facilities was 4.6 and 19.2% among
CHW. In the private sector, 77.6% of all anti-malarial
stockists had chloroquine available. Chloroquine availability was highest among anti-malarial stocking general
retailers (96.9%), followed by pharmacies (74.6%) and private for-profit facilities (49.3%).

100

PERCENT OF OUTLETS

90
80
70
60
50
40
30
20
10
0

Public
Health
Facility
N=95

Community
Health
Worker
N=463
Public Sector

Total
Public
Sector
N=558

Private
for-Profit
Health
Facility
N=172

Pharmacy
N=479

Drug
Store
N=15

General
Retailer
N=6,295

Private Sector

Fig. 1 Percentage of all screened outlets with at least one anti-malarial in stock on the day of the survey

Itinerant
Drug
Vendor
N=67

Total
Private
Sector
N=7,586
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Table 1 Availability of anti-malarials and malaria blood testing, among anti-malarial stockists
Public health
facility

Community
health worker

Public sector
total

Private for-profit Pharmacy
facility

General retailer

Private sector
total

%
(95% CI)

%
(95% CI)

%
(95% CI)

%
(95% CI)

%
(95% CI)

%
(95% CI)

%
(95% CI)

Proportion
of outlets stock‑
ing:

N = 91

N = 145

N = 236

N = 56

N = 309

N = 23

N = 394

Any national firstline ACT (AL)

99.5
(97.1, 99.9)

83.1
(72.3, 90.3)

88.8
(82.0, 93.2)

63.3
(45.8, 77.9)

51.7
(40.0, 63.2)

3.1
(0.5, 17.0)

40.8
(31.1, 51.2)

Chloroquine

4.6
(1.9, 10.6)

19.2
(11.2, 31.0)

14.1
(8.9, 21.7)

49.3
(33.7, 65.0)

74.6
(67.0, 80.9)

96.9
(83.0, 99.5)

77.6
(71.2, 83.0)

Primaquine

6.7
(1.57, 24.17)

0.0
–

2.8
(0.6, 12.13)

0.0
–

0.0
–

0.0
–

0.0
–

Oral artemisinin
monotherapy

0.0
–

0.0
–

0.0
–

2.7
(0.5, 14.5)

0.0
–

0.0
–

0.3
(0.0, 1.6)

N = 91

N = 154

N = 255

N = 58

N = 327

N = 30

N = 424

Any malaria blood 90.8
testing
(77.4, 96.6)

78.4
(66.7, 86.9)

82.4
(74.2, 88.3)

77.0
(64.3, 86.2)

55.7
(44.2, 66.7)

6.1
(1.6, 20.6)

43.5
(34.2, 53.3)

Malaria microscopy

23.1
(14.9, 34.0)

0.0
–

7.3
(4.6, 11.4)

16.0
(9.4, 25.8)

0.3
(0.0, 1.7)

0.0
–

1.7
(1.0, 2.9)

Rapid diagnostic
tests

85.4
(73.5, 92.5)

78.4
(66.7, 86.9)

80.6
(72.3, 86.9)

77.0
(64.3, 86.2)

55.7
(44.2, 66.7)

6.1
(1.6, 20.6)

43.5
(34.2, 53.3)

AL artemether–lumefantrine

Primaquine was generally not available across the public or private sector, with the exception of anti-malarial
stocking public health facilities (6.7%). Of the 7586 outlets screened, only one box of oral artemisinin monotherapy was found.
Among public health facilities, 90.8% of anti-malarial
stockists had malaria blood testing; 85.4% had RDTs in
stock on the day of survey and 23.1% had malaria microscopy. Among CHWs, 78.4% had RDTs in stock on the day
of survey. Within the private sector, malaria blood testing
was available in 77.0% of private for-profit facilities and
55.7% of pharmacies, and typically stocked RDTs.
Anti‑malarial market share

Figure 3 shows the relative anti-malarial market share in
the public and private sector. All anti-malarials reportedly distributed in the southern Lao PDR were either AL
or chloroquine, and most anti-malarials distributed were
chloroquine treatments (62.2%). Almost all the chloroquine
distributed was through the private sector. In contrast, AL
was almost exclusively distributed by the public sector.
The public sector accounted 32.3% of the total antimalarial market share, including public health facilities
(23.4%) and CHWs (8.9%). Private sector market share
was 64.5 and 49.9% of all anti-malarials distributed were
distributed by pharmacies. Private for-profit facilities and
general retailers each accounted 7.2 and 6.6% of the market share, respectively.

Provider anti‑malarial treatment knowledge

Table 2 illustrates provider knowledge to correctly state
the national first-line treatment for uncomplicated P.
falciparum or P. vivax malaria. Provider knowledge
was 77.9% in the public sector and 40.4% in the private sector. Correct knowledge of the dosing regimen
was 58.2% in the public sector (N = 255) and 30.2%
in the private sector (N = 424). Provider knowledge
was highest among public health facilities regarding
the first-line treatment (89.5%) and first-line dosing
regimen (73.0%). Among pharmacies, 49.5% could correctly state the first-line treatment for P. falciparum or
P. vivax malaria.
Chloroquine insights

Most of the chloroquine distributed was in tablet formulation (94.8%), and other formulations included injections
(5.2%) and syrups (<1%). The most commonly available
chloroquine product was Maraquine®, a tablet produced
in the Lao PDR by CBF pharmaceuticals. M
 araquine®
accounted for 74.9% of all audited chloroquine products
and for 50.5% of all anti-malarials distributed. Amongst
all anti-malarial stocking private sector outlets, 28.9% of
providers reported chloroquine was the most effective
treatment for uncomplicated malaria. 32.7% of private
sector providers reportedly recommended chloroquine
most often for treatment of uncomplicated malaria in
adults (Additional file 4).
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Table 2 Provider anti-malarial treatment knowledge by outlet type
Public health
facility

Community
health worker

Public sector
total

Private for-profit Pharmacy
facility

General retailer

Private sector
total

%
(95% CI)

%
(95% CI)

%
(95% CI)

%
(95% CI)

%
(95% CI)

%
(95% CI)

%
(95% CI)

N = 91

N = 164

N = 255

N = 58

N = 327

N = 30

N = 424

Correctly state the 89.5
national first-line (81.7, 94.2)
treatment for
uncomplicated
P. falciparum/
vivax malaria, AL

72.6
(64.7, 79.3)

77.9
(72.0, 82.9)

78.7
(63.8, 88.5)

49.5
(39.0, 60.0)

8.1
(2.7, 21.9)

40.4
(31.6, 49.8)

Correctly state
the first-line
(AL) dosing
regimen for
uncomplicated
P. falciparum/
vivax malaria for
an adult

51.3
(41.0, 61.5)

58.2
(49.6, 66.3)

66.4
(51.1, 78.8)

36.5
(28.0, 46.0)

6.1
(1.6, 20.6)

30.2
(23.1, 38.2)

Proportion
of providers
who:

73.0
(60.7, 82.5)

AL artemether–lumefantrine

Key indicators among private sector outlets in PPM
and non‑PPM districts

This sub-section presents results among anti-malarial
stockists located in designated PPM districts and in nonPPM districts (Table 3). Among the 264 private pharmacies and for-profit health facilities in PPM districts, 68.1%
were stocking the AL and 72.6% were stocking malaria
blood testing. Availability of AL in 101 pharmacies and
private clinics in outlets located in non-PPM districts
was 2.5%. Only 12.1% of pharmacies and private clinics in non-PPM districts had any malaria blood testing.

96.7% of anti-malarial stockists in non-PPM districts
were stocking chloroquine compared to 63.6% in PPM
districts.
Provider knowledge of the first-line treatment for
uncomplicated P. falciparum or P. vivax malaria was
65.0% in private sector outlets in PPM districts and 15.0%
in the non-PPM districts. In PPM districts, 51.0% of providers correctly stated the first-line dosing regimen for
uncomplicated P. falciparum or P. vivax compared with
only 6.1% of providers in private sector non-PPM district
outlets. Providers that reportedly received a supervisory
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Table 3 Key Indicators among pharmacies and private forprofit health facilities in PPM versus non-PPM districts

Proportion of antimalarial stockists with:
Any national first-line
ACT (AL)
Chloroquine

PPM district outlets

Non-PPM district
outlets

%
(95% CI)

%
(95% CI)

N = 264

N = 101

68.1

2.5

(59.7, 75.4)
63.6

(0.9, 6.8)
96.7

(56.5, 70.2)

(92.3, 98.6)

N = 275

N = 110

(66.5, 78.0)

(6.6, 21.0)

Proportion of providers frwho:

N = 275

N = 110

Correctly state the
national first-line treatment for uncomplicated P. falciparum/
vivax malaria

65.0
(57.3, 72.0)

15.0
(7.6, 27.6)

Correctly state the first51.0
line dosing regimen
(43.9, 58.0)
for uncomplicated P. falciparum/vivax malaria
for an adult

6.1
(2.7, 13.4)

Any confirmatory testing

72.6

N = 155

12.1

N = 36

Report receiving a super- 74.5
visory or regulatory visit (61.6, 84.3)
within the past year

17.0
(4.1, 49.4)

Median price

Median
[IQR](N of Anti-malarials)

National first-line ACT
(AL) AETD #
Chloroquine AETD #

Median
[IQR](N of Anti-malarials)
$0.00
[0.00–0.00] (516)
$0.62
[0.62–0.62] (173)

Rapid diagnostic test

$0.00
[0.00–0.25] (216)

$0.00
[0.00–0.00] (3)
$0.62
[0.47–0.62] (103)
$3.12
[2.50–3.75] (38)

AL artemether–lumefantrine, AETD adult equivalent treatment dose, IQR
interquartile range

or regulatory visit within the past year was 74.5% in private sector outlets in PPM districts and 17.0% in nonPPM districts.
AL was reportedly provided free-of-charge in private
sector PPM district outlets. The retail price of chloroquine was the same ($0.62) in private sector outlets in
PPM and non-PPM districts. In PPM districts, RDTs
were provided free-of-charge in the private sector. The
median price of an RDT in non-PPM district private sector outlets was $3.12.
Figure 4 illustrates the total anti-malarial distribution
among private for-profit facilities and pharmacies located
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within the PPM and non-PPM districts. Chloroquine distribution was 99.1% among private sector outlets located
in the non-PPM districts and 61.7% in outlets located in
the PPM district. Distribution of AL in the week prior to
the survey was only observed among the private sector
outlets located in PPM districts (38.3%).

Discussion
The 2015 outlet survey was the first anti-malarial market
survey of its kind implemented in the southern Lao PDR.
The outlet survey provided a complete picture of the
malaria testing and treatment landscape across the public
and private sectors with information on availability, price
and market share as well as provider knowledge. The data
show strong public sector readiness for proper malaria
case management. Findings point to recommendations
for rapidly improving coverage of appropriate malaria
case management by reducing availability and market
share of chloroquine in the private sector and to expand
the PPM programme.
Public sector readiness for appropriate malaria case
management

Findings from the 2015 ACTwatch outlet survey show
high public sector readiness for appropriate malaria case
management in the southern Lao PDR. Nearly all public
health facilities stocked the national first-line ACT, and
confirmatory testing was available in over 90% of antimalarial stocking public facilities.
The reach of the public sector has been extended to the
community-level through the training and equipping of
village malaria workers and village health volunteers with
malaria case management skills and supplies. CHWs are
playing an important part in provision of malaria case
management services. They accounted for over 40% of
all anti-malarial stockists, and distributed nearly 10% of
all anti-malarials. Maintaining a network of trained and
equipped CHWs is part of the strategy in the Lao PDR
for achieving high malaria case management coverage
and ultimately malaria elimination. Key challenges to be
addressed as the Lao PDR attempts to achieve its goal of
eliminating malaria by 2030 include gaps in CHW motivation and retention, training and maintaining supervision [1]. Results from this outlet survey suggest that in
addition to these challenges, the availability of the nonfirst-line drug, chloroquine, must be addressed as this
was available among one in five CHWs.
Primaquine is included in the national treatment guidelines as part of the first-line treatment for P. falciparum/P.
vivax along with AL [9]. The results showed how availability of primaquine was negligible across all the public sector. At the time of the survey, primaquine had not
been widely procured or distributed due primarily to
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concerns of adverse health reactions in patients with glucose-6 phosphate dehydrogenase (G6PD) deficiency. Two
primaquine products were audited in the 2015 outlet
survey and these were found in public district hospitals.
The availability of primaquine in these outlets was likely
due to a 2015 WHO-supported pilot study, which was
conducted to assess G6PD testing and primaquine dispensing capabilities at selected district hospitals in three
provinces. The presence of these products likely reflect
leftover stock from the pilot study. Wider procurement
of G6PD tests and primaquine is planned for 2016 as the
national strategy expands to introduce primaquine more
widely to treat P. falciparum and radically cure P. vivax
infections in patients without G6PD deficiency [1, 10].
Role of the private sector in appropriate malaria case
management

The private sector plays an important role in malaria
case management in the southern Lao PDR, as results
from this 2015 outlet survey show that the private sector was responsible for approximately 60% of all antimalarial distribution, a finding corroborated by other
population based research [5]. Indeed, the private sector
has played a predominant role in malaria case management in other countries in the Greater Mekong Subregion (GMS) region, including neighboring Cambodia [11,
12]. In the Lao PDR, the private sector for malaria case
management includes both formal, regulated outlet
types like private for-profit facilities and pharmacies as
well as informal, unregulated outlet types such as drug
stores, general retailers and itinerant drug vendors. Pharmacies were the most common type of private outlet

stocking anti-malarials during the 2015 outlet survey, and
accounted for nearly one in four anti-malarial stockists.
The private sector was generally less well-equipped to
test and appropriately treat malaria infections as compared with the public sector. Fewer than half of antimalarial-stocking private sector outlets were stocking
the national first-line ACT, and fewer than half had confirmatory testing available. The majority of private sector
outlets had the non-first-line drug, chloroquine, in stock.
Widespread availability and use of chloroquine

Replaced by AL as the first-line treatment for P. falciparum in 2005 and P. vivax in 2011, chloroquine is now
part of the national treatment guidelines as a secondline treatment for uncomplicated P. vivax, Plasmodium
ovale and Plasmodium malariae infections. However, the
availability of the second-line drug, chloroquine, should
be limited, and with the drug found primarily in public
health facilities equipped to detect and manage AL treatment failure. The results from this outlet survey illustrate
how 10 years after the change in first-line treatment for P.
falciparum and 5 years after the change in first-line treatment of P. vivax, chloroquine remained widely available
and distributed, particularly in the private sector. The
widespread popularity of chloroquine has been documented elsewhere [13], and its common presence on the
market suggests it is being distributed as a first-line for
treatment of uncomplicated malaria.
One driver of chloroquine popularity in the Lao PDR
could be the accessibility of Maraquine®, an inexpensive,
chloroquine tablet pre-packaged for individual treatment and manufactured locally by CBF pharmaceuticals
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(see Additional file 5). The Lao script makes the packaging understandable and recognizable to providers and
potential customers alike. M
 araquine® accounted for
three-quarters of all chloroquine audited during the outlet survey, and accounted for half of all anti-malarials distributed in the southern Lao PDR. As a widely available
product, Maraquine® represents a significant roadblock
to AL uptake in the Lao PDR’s private sector. Further
research is required to understand Lao consumer and
provider preferences for this product, and new strategies
are necessary to curtail the consumption of chloroquine
and promote the use of the recommended first-line treatments, especially in the private sector.
Public private mix

Significant efforts have been made in the southern Lao
PDR to engage the private sector towards improving
provider practices. The PPM was launched in 2008 with
the aim of supporting, rather than discouraging pharmacies and for-profit health facilities to manage malaria
cases appropriately. As such, the PPM programme has
expanded access to proper testing and treatment in the
highly utilized private sector [4]. On a promising note,
the 2015 outlet survey demonstrated that the PPM programme had higher availability of first-line treatment
and confirmatory blood testing as compared with private outlets that were not part of the PPM programme.
In 2015, nearly all of the AL distributed by the private
sector was distributed by outlets located in the designated PPM districts, and private sector availability of
confirmatory testing was largely restricted to PPM districts. This suggests the PPM programme has potential
for wider reach and impact with the addition of supporting interventions to address provider and consumer
behaviour.
Despite high coverage with training and supervision,
as well as moderate levels of provider knowledge regarding first-line treatment, chloroquine was still commonly
stocked and distributed by these PPM providers. This
suggests a delay in the uptake of subsidized anti-malarials, a finding that has been widely documented by other
countries in the region [14–16]. Cambodia provides
an example of a programme with a long history of subsidized first-line treatment in the private sector, and
through an increasingly regulated private sector channel. Repeated outlet surveys have shown that while ACT
availability has increased, market share has been slower
to follow suit [17]. Evidence has pointed to the importance of necessity of considering provider and consumer
factors that may influence first-line treatment uptake, as
well as the national regulatory environment.
The market share findings point to the need for new
strategies, or an intensification of existing ones, to
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completely remove chloroquine from the market. One
important barrier to consider is the recommended price
of the subsidised AL treatment. Providers participating
in the PPM project may lack adequate financial incentives as compared with other subsidy models [18–21]. As
part of the PPM programme, providers are permitted to
charge 1000 Lao Kip ($0.12) for a treatment dose of AL
and 2000 Lao Kip ($0.25) for an RDT [4]. By comparison,
the median price of a treatment dose of chloroquine was
$0.62. Although private sector providers may be stocking AL, they may be financially incentivized to dispense
chloroquine given the profit margins they make, especially in light of the evidence that they typically distribute AL free-of-charge. Providers have reported that they
can offset free distribution of AL by making profits on
accompanying goods including vitamins and paracetamol, suggesting that profit is indeed important [4]. Future
strategies may want to consider addressing provider
financial incentives as well as consumer willingness to
pay.
There is also likely a need for supporting interventions
to drive consumer awareness and demand for AL [21].
Indeed, studies have suggested that customer demand
influences retailer ACT dispensing behaviour [22], such
that the odds of a patient receiving first-line treatment
was found to be significantly associated with patient
demand across both public and private sector facilities [23]. However, in general very little is known about
malaria treatment-seeking behaviour and drivers of
consumer behaviour in the Lao PDR. Though some key
reviews were published in the 1990s [24, 25], evidence
gaps exist. Effective strategies to drive demand for ACT
will require additional evidence about consumer preferences and behaviours.
Oral artemisinin monotherapy

Oral artemisinin monotherapy poses a serious threat to
the continued efficacy of artemisinins in the Lao PDR
and across the region, and as such this anti-malarial was
banned in the Lao PDR in 2008. This ban has been sporadically enforced by the Food and Drug Department. In
addition to ban enforcement, the promotion of free firstline ACT, initially in the public sector and now through
the PPM programme, has been the main tool used to
reduce the availability of oral AMT in the Lao PDR.
Previous studies have documented availability of oral
artemisinin monotherapy in the private sector of GMS
countries, including the Lao PDR [26]. Over 7500 outlets
were screened during the 2015 outlet survey and just one
box of oral artemisinin monotherapy (artesunate tablets)
was found. Outlet survey results were consistent with
recent research that has demonstrated a marked decrease
in oral artemisinin monotherapy availability over time
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[13]. The removal of oral artemisinin monotherapy from
the market in the Lao PDR is a success shared by neighboring Cambodia [12], but this remains a serious problem in another GMS country, Myanmar [27].

Limitations
The ACTwatch outlet survey design has limitations that
have been documented elsewhere [6, 28]. Specific to the
outlet survey in the Lao PDR, data collection was conducted just after peak malaria season (July–October),
between mid-November and the end of December, 2015.
Outlet surveys are ideally conducted during peak transmission season to avoid fluctuations in stocking key commodities that may occur outside of peak season.
The outlet survey entails an audit of all available malaria
commodities. Providers may have chosen to hide certain
anti-malarial products. However, similar results were
obtained through use of a mystery client study design
implemented in the southern Lao PDR [13], suggesting
that the outlet survey findings regarding very low levels
of oral artemisinin monotherapy availability are valid.
The outlet survey was not designed to evaluate the
PPM programme. PPM district status was determined
post-data collection and analyses examined private sector readiness and performance in districts with and without the PPM programme. More rigorous evaluation of
the PPM programme is needed, with a study designed to
measure implementation strength and to compare outlets that are designated as PPM and non-PPM.
This outlet survey was also not explicitly designed
to evaluate the malaria CHW programme. CHWs in
selected clusters were screened to assess availability of
malaria testing and treatment regardless of reported
malaria case management training. While most CHWs
approached were either Village Malaria Workers or
Village Health Volunteers trained and equipped for
malaria test and treat services, it is feasible that some
Village Health Volunteers screened were not part of the
malaria programme. This may have artificially increased
the total number of CHWs included in the denominator
therefore deflating estimates of the indicator showing
the availability of any anti-malarial, among all screened
CHWs.
The most senior provider was interviewed at each
outlet for this survey. Senior-most providers were interviewed as they are generally in the best position to
provide the most accurate reports of price, sales, availability, stock outs and service readiness. Some bias could
have been introduced in that key indicators on provider
knowledge only reflect answers from these better trained
providers. Therefore, knowledge of first-line treatment
and appropriate regimen may have been lower if lowerlevel providers were interviewed for this survey.
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While all of the ACT that was audited in the Lao PDR
was quality-assured, it should be acknowledged that this
quality-assurance status granted by regulatory authorities does not necessarily preclude manufacturing quality
failures or prevent conditions or practices that may lead
to drug degradation over time. Moreover, anti-malarial
treatments that have not been granted pre-qualification
status or regulatory approval may be safe and efficacious.
Nonetheless, quality-assurance status has been associated with high quality medicines in field drug quality
studies [22]. Further research in the Lao PDR is necessary
to address the quality of anti-malarial treatments and
complement previous evidence on this topic [13].
Finally, while the current outlet survey provided supply
side data on the anti-malarial and diagnostic markets of
the southern Lao PDR, further information is merited to
understand the demand side which this outlet survey did
not investigate. A malaria indicator survey implemented
in the Lao PDR would provide important and complementary evidence to the data presented herein.

Conclusions
Public sector outlets in the southern Lao PDR are typically equipped to test and appropriately treat malaria
according to national treatment guidelines. However,
the private sector is responsible for the majority of antimalarial distribution. As such there is need to address the
widespread private sector availability and distribution of
the non-first-line drug, chloroquine. Evidence suggests
that the PPM programme approach has been successful
in introducing first-line ACT and RDTs and improving
readiness of private providers to manage malaria according to national guidelines. However, despite provision
of training, supervision and key commodities, private
providers continue to stock and distribute chloroquine.
Supporting interventions to address provider and consumer behaviours are needed to drive uptake of first-line
treatment.
Additional files
Additional file 1. The Lao PDR ACTwatch Survey Questionnaire (English).
Additional file 2. The Lao PDR ACTwatch Survey Questionnaire (Lao).
Additional file 3. Detailed sample description.
Additional file 4. Provider perceptions regarding the most effective
treatment for uncomplicated malaria.

Additional file 5. Maraquine®, a locally manufactured and popular
anti-malarial.
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